Story perspectives

J&J Agrees to Pay Up to $5.5 B in Talc Lawsuit Settlement

7/28/2026

Summary

J&J Settles Talc

Johnson & Johnson agreed to pay up to $5.5 billion to settle ovarian-cancer lawsuits over its talc baby powder.
The settlement covers about 69,000 claims—roughly 99.75 percent of remaining U.S. cases—and becomes final only if 95 percent of claimants accept it, with $3 billion due in 2027 and further payments in 2028.
Kenvue, J&J’s 2022 consumer-health spinoff, holds liability for baby-powder sold outside North America, while J&J says the talc is safe and asbestos-free.

Summary

J&J Warns Settlement

Johnson & Johnson filed forward-looking statements about the settlement in its Form 10-Q quarterly report, publicly available online.
The company warned that results could differ because of litigation, regulatory actions, product recalls, and directed investors to its Form 10-K for a list of uncertainties, including patent challenges and technology advances.
Johnson & Johnson cautioned that the settlement information should not be taken as a commitment to any specific future strategy or action.

1 of 2

J&J Settles Talc

Johnson & Johnson agreed to pay up to $5.5 billion to settle ovarian-cancer lawsuits over its talc baby powder.
The settlement covers about 69,000 claims—roughly 99.75 percent of remaining U.S. cases—and becomes final only if 95 percent of claimants accept it, with $3 billion due in 2027 and further payments in 2028.
Kenvue, J&J’s 2022 consumer-health spinoff, holds liability for baby-powder sold outside North America, while J&J says the talc is safe and asbestos-free.

1 / 2